Introduction
Red blood cells, the most abundant of all circulating blood cells, facilitate gas exchange in the lungs and transporting oxygen to tissues. More than two million red blood cells are generated per second in a healthy adult through a process termed erythropoiesis. Mature red blood cells are produced from hematopoietic stem cells, which commit to erythroid progenitors followed by terminal erythroid differentiation. Terminal erythroid differentiation, driven by the glycoprotein hormone erythropoietin, begins with proerythroblasts, which sequentially divide into basophilic, polychromatic and orthochromatic erythroblasts that enucleate to generate reticulocytes. 1, 2 Erythropoiesis is a tightly regulated process. Previous studies were primarily focused on the regulation of erythropoiesis by transcription factors and cytokines. 3, 4 In contrast, the regulation of erythropoiesis by other mechanisms has been less well studied. Notably, our knowledge on post-translational regulation of erythropoiesis is limited.
Ubiquitination is an enzymatic post-translational modification. Ubiquitinated proteins are degraded by the ubiquitin-proteasome system (UPS). The UPS controls the degradation of most intracellular proteins and plays important roles in many cellular processes. 5 Although the UPS was first discovered in reticulocytes over 40 years ago, 6 to date there are only limited studies on the roles of the UPS in erythropoiesis. These include the reported role of CUL4A-mediated degradation of p27 in cell proliferation in the early stages of erythropoiesis and cell cycle exit at a later stage of erythropoiesis. 7, 8 A recent, exciting study demonstrated that UBE2O remodels the proteome during terminal erythroid differentiation, underscoring the importance of the UPS in erythropoiesis. 9 Ubiquitination is a dynamic and reversible process. 10 It has been reported that deubiquitylases are capable of removing ubiquitin from their protein substrates and allow proteins to be salvaged from proteasomal degradation. 11 USP7 is a deubiquitylase that belongs to the ubiquitin-specific protease (USP) family, which constitutes the largest subgroup of deubiquitylases. Accumulated evidence has shown that USP7 plays diverse roles in genome stability, epigenetic regulation, the cell cycle, apoptosis, viral infection, immunity and stem cell maintenance. [12] [13] [14] [15] [16] [17] Recently, USP7 was reported to be an important regulator of osteogenic differentiation and adipogenesis. 18, 19 Our RNA-sequencing analyses revealed highlevel expression of genes/pathways (including USP7) involved in the ubiquitin system during late stages of terminal erythroid differentiation. 2 Nevertheless, the function of USP7 in human erythropoiesis remains unexplored.
GATA1 is the key transcription factor for erythropoiesis, controlling the expression of a large series of erythroid genes, including erythropoietin receptor, globins and several membrane proteins. 20 GATA1-deficient mice die in utero due to severe anemia at embryonic day 10.5-11.5, 21 and chimeric mice lacking GATA1 fail to produce mature red blood cells, although the formation of cells of other hematopoietic lineages is normal. 22 In contrast, overexpression of GATA1 in erythroid cells inhibits their differentiation, leading to fatal anemia in mice. 23 GATA1 stability is finely regulated by multiple mechanisms, 24 since changes in its protein levels will exert a great influence on erythropoiesis. Although GATA1 degradation by the ubiquitin-proteasome pathway has been characterized, 24 how GATA1 recycles from the UPS is yet to be defined.
In this study, we demonstrated that USP7 deficiency impairs human terminal erythroid differentiation due to a decreased level of GATA1 protein. We further showed that USP7 interacts directly with GATA1 and catalyzes the removal of poly-ubiquitylation chains on GATA1, thus stabilizing GATA1. Our findings have thus not only documented the role of a deubiquitylase in erythropoiesis, but also enabled the identification of a novel mechanism by which deubiquitylases regulate GATA1 protein stability.
Methods

Reagents and antibodies
P5091 (S7132) and MG132 (S2619) were obtained from Selleckchem (TX, USA); P22077 (HY-13865) from MCE (NJ, USA); and cycloheximide was purchased from Sigma-Aldrich (MO, USA). Antibodies used for western blot, immunoprecipitation and immunofluorescence studies are detailed in the Online Supplementary Methods. The antibodies used for flow cytometry analysis were glycoprotein A (GPA)-PE-Cy7, GPA-APC, and α4integrin (CD49d)-PE from BD Pharmingen (NJ, USA). Band 3-APC and 4.1R antibodies were used as previously described. 25 
Cell culture
Human cord blood samples were obtained from Xiangya Hospital of Central South University or New York Blood Center under Institutional Review Board approval and in accordance with the Declaration of Helsinki. The detailed composition of the culture medium and the cell culture protocol has been described previously. 25 HEK293T cells (American Type Culture Collection: CRL-11268) were cultured in Dulbecco modified Eagle medium (Gibco, MA, USA) supplemented with 10% fetal bovine serum (Gibco).
Lentivirus packaging and infection
USP7-specific short hairpin (sh)RNA was purchased from GenePharma (Shanghai, China) (shRNA #1: 5'-AGTCGTTCAGTCGTCGTAT-3' and #2: 5'-TGGATTTGTG-GTTACGTTACTC-3', constructed in pGLV3-H1-GFP or pGLV2-U6 vector). GATA1 overexpression (HMD-GATA1-IRES-GFP) and control plasmids have been described previously. 26 Lentiviruses were packaged in HEK293T cells according to the manufacturer's protocol (Invitrogen, MA, USA). A total of 30x10 7 lentiviral particles were infected using polybrane with 0.5x10 7 CD34 + cells on day 3 or 4. Puromycin (1 mg/mL) was used for selection of transduced cells.
GATA1 rescue assay
For rescue experiments, erythroid cells were infected with USP7 shRNA or control shRNA lentiviruses for 3 days. On day 7 of culture, erythroid cells were transduced with the control or GATA1 lentivirus. Double-transduced cells were identified following puromycin (1 μg/mL) selection and GFP expression from the HMD vector. The extent of terminal erythroid differentiation was monitored beginning on day 9.
RNA isolation, quantitative real-time polymerase chain reaction and western blot analysis.
Standard protocols were used for RNA and protein isolation, polymerase chain reaction (PCR) and western blot analysis. Details are given in the Online Supplementary Methods. The GATA1 primer sequences were described previously. 27 USP7 primer sequences were: forward: 5'-AGCGTGGCATCACCATAATC-3' and reverse: 5'-CGAGGCAACCTTTCAGTTCA-3'.
Immunoprecipitation and glutathione-S-transferase pull-down
Immunoprecipitation studies were performed using M2/Flag or protein A/G-agarose beads. For the glutathione-S-transferase (GST) pull-down assay, purified Flag-USP7 and bacterial expressed GST or GST-GATA1 were used. The methods are described in detail in the Online Supplementary Methods.
In vivo ubiquitylation and deubiquitylation assays
For cell-based deubiquitylation assays, Flag-GATA1 and HAubiquitin were co-transfected with an empty vector or a vector expressing USP7 (WT or CS) for 48 h. For USP7 knockdown, the cells were infected with the lentiviruses for 48 h. Additional details of the methods are given in the Online Supplementary Methods.
In vitro deubiquitylation assays
In vitro ubiquitylation assays were performed as previously described 28 and additional details are provided in the Online Supplement.
Statistical analysis
All data are presented as mean ± standard deviation (SD), and the results were analyzed using the SPSS 18.0 software package. Significant differences between groups were determined using analysis of variance and the Tukey range test.
Results
Deficiency of USP7 impairs human terminal erythroid differentiation
To explore the roles of deubiquitylases during erythropoiesis, we first analyzed the expression patterns of deubiquitylases in human erythroblasts at different stages of differentiation from our RNA-sequencing data. 2 Figure 1A shows the expression patterns of USP family members and reveals that the expression levels of USP7 are significantly increased during erythropoiesis. Based on the previously identified important role of USP7 in cell differentiation in other cellular systems, [17] [18] [19] in the present study we focused our attention on the role of USP7 in erythroid differentiation. We confirmed the increased expression of USP7 during late stages of erythroid differentiation by both real-time PCR ( Figure 1B ) and by western blot analysis ( Figure 1C ). To examine the effect of USP7 on erythropoiesis, we employed a shRNA-mediated knockdown approach in human CD34 + cells. 27, 29, 30 As shown in Figure  1D , USP7 knockdown impaired the terminal erythroid differentiation as demonstrated by the decreased surface expression of the erythroid marker GPA, delayed loss of α4-integrin expression in association with decreased surface expression of band 3. There was also a marked decreased in the extent of enucleation. USP7 knockdown also inhibited the expression of hemoglobin ( Figure 1E ). The significant impairment of the growth of late-stage erythroblasts caused by USP7 knockdown was accompanied by increased apoptosis (Online Supplementary Figure  S1A , B). Similar to USP7 knockdown, USP7-specific inhibitors P5091 and P22077 31,32 also impaired human terminal erythroid differentiation, inhibited hemoglobin expression ( Figure 1F , G) and cell proliferation (Online Supplementary Figure S1C, D) . These results imply that USP7 plays an important role in human terminal erythroid differentiation.
USP7 regulates erythroid differentiation by modulating GATA1 protein levels
We subsequently explored the molecular mechanism(s) of the altered erythropoiesis due to USP7 deficiency. Given the fact that USP7 functions in the nucleus, 33, 34 we hypothesized that USP7 might affect erythropoiesis by regulating erythroid differentiation-related transcription factors. As shown in Figure 2A and Online Supplementary Figure S2 , GATA1 was the transcription factor most significantly decreased after knockdown of USP7, although KLF1 levels also decreased. Since KLF1 expression is regulated by GATA1, 35 we suggest that the decreased expression of KLF1 is a consequence of GATA1 downregulation. Interestingly, mRNA levels of GATA1 were not affected by USP7 knockdown on day 9 ( Figure 2B ), suggesting that the observed decrease in GATA1 levels is at the post-transcriptional level. We noted decreased levels of GATA1 mRNA levels on days 11 and 13 following USP7 knockdown (Online Supplementary Figure S3A, B) , likely due to the fact that GATA1 mediates its own regulation at the late stages of erythropoiesis. 36, 37 Similarly, inhibition of USP7 activity by the USP7-specific inhibitors P5091 and P22077 also resulted in significant decreases in GATA1 protein levels in a dose-dependent manner ( Figure 2C, D) , with no obvious effects on other transcription factors beside a slightly decreased expression of KLF1 (Online Supplementary Figure S4) , implying that USP7-mediated regulation of GATA1 depends on the enzymatic activity of USP7. To further confirm that USP7 deficiency-induced defective erythropoiesis is due to downregulation of GATA1, we performed rescue experiments by ectopically expressing GATA1 in USP7 knockdown cells. Figure 2E shows that the delayed erythroid differentiation as well as impaired erythroblast enucleation could be rescued by restoring GATA1 levels. Furthermore, the expression of GATA1 target genes such as 4.1R and HBG were also rescued ( Figure 2F ). These results imply that USP7 regulates erythroid differentiation through GATA1.
USP7 regulates the stability of the GATA1 protein
GATA1 protein levels are regulated by several proteins, including HSP70, a GATA1 chaperone [38] [39] [40] and RPS19, necessary for GATA1 translation. 26, 41 To examine whether HSP70 and RPS19 are involved in the regulation of GATA1 mediated by USP7, we analyzed the effect of USP7 knockdown on their expression levels. As shown in Online Supplementary Figure S5A , B, USP7 knockdown or inhibition had no effects on HSP70 or RPS19 protein levels. Moreover, USP7 knockdown did not affect the translocation of HSP70 into the nucleus (Online Supplementary Figure  S5C , D). The above findings strongly suggest that USP7 regulates the stability of GATA1 protein directly. We performed several additional studies to confirm this hypothesis and to define the underlying mechanisms. First, coexpression of wildtype USP7 (USP7-WT) with GATA1 increased the GATA1 level ( Figure 3A) . Importantly, catalytically inactive mutant USP7 (USP7-CS, C233S) did not increase GATA1 protein levels ( Figure 3B ). Second, downregulation of GATA1 by USP7 knockdown or the USP7 inhibitors P5091 and P22077 was reversed by the proteasome inhibitor MG132 ( Figure 3C -E), implying that USP7 maintains the steady-state levels of GATA1 by blocking its proteasomal degradation. To further examine the relationship between USP7 and GATA1, we measured the half-life of intracellular GATA1 after cells had been treated with cycloheximide to inhibit protein biosynthesis. As shown in Figure 3F , knockdown of USP7 significantly shortened the half-life of the GATA1 protein. Conversely, overexpression of USP7-WT, but not USP7-CS, prolonged the half-life of GATA1 ( Figure 3G ). Taken together, our data demonstrate that USP7 stabilizes GATA1 by preventing its proteasomal degradation.
USP7 interacts directly with GATA1
Having demonstrated that USP7 stabilizes GATA1, we then examined whether this effect is through their direct interaction by performing co-immunoprecipitation experiments. USP7 or GATA1 was separately immunoprecipitated from cultured primary erythroblasts and the reciprocal protein was detected by western blot analysis. As Figure 4A , endogenous USP7 was immunoprecipitated by anti-GATA1 antibodies but not by control IgG. Conversely, GATA1 was immunoprecipitated by anti-USP7 antibodies but not by control IgG (Figure 4B ).
To determine whether USP7 and GATA1 interact directly with each other, we performed GST pull-down assays under a cell-free condition by using purified recombinant GST-GATA1 and Flag-USP7 proteins. As shown in Figure  4C , the purified GST-GATA1 but not the control GST was able to pull down USP7. Furthermore, we mapped the detailed binding region of GATA1 and USP7 in HEK293T cells, a non-erythroblast environment. 38, 42, 43 Truncation mutants of GFP-USP7 and Flag-GATA1 were co-transfected into HEK293T cells and co-immunoprecipitation analyses revealed that the N-terminal TRAF-like domain (1-208) of USP7 was critical for the interaction between GATA1 and USP7 ( Figure 4D ). Conversely, mapping the region of GATA1 required for USP7 binding showed that the DNA binding domain (200-290) of GATA1 was responsible for its interaction with USP7 ( Figure 4E ). Collectively, these results show that USP7 interacts with GATA1 directly.
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USP7 stabilizes GATA1 protein through K48 deubiquitylation
Since USP7 is a deubiquitylase, it is reasonable to speculate that USP7 regulates the stability of GATA1 via deubiquitylation. To test this hypothesis, we investigated the effect of USP7 on the poly-ubiquitylation of GATA1. As expected, knockdown of USP7 resulted in a significant increase in the poly-ubiquitylation of GATA1 ( Figure 5A) . In contrast, ectopic expression of USP7-WT but not the catalytic inactive mutant USP7-CS reduced the level of poly-ubiquitylation of GATA1 ( Figure 5B and Online Supplementary Figure S6A) . Moreover, USP7-mediated decrease of GATA1 poly-ubiquitylation was blocked by the USP7 inhibitors P5091 and P22077 ( Figure 5C and Online Supplementary Figure S6B) , demonstrating that the enzymatic activity of USP7 is essential for the USP7-mediated deubiquitylation of GATA1. To verify that GATA1 is a direct substrate of USP7, the purified USP7 protein was incubated with ubiquitylated GATA1 in a cell-free system. As shown in Figure 5D , GATA1 poly-ubiquitylation was decreased in the presence USP7, indicating that USP7 deubiquitylates GATA1 directly. To determine which polyubiquitin chain on GATA1 is removed by USP7, we employed a series of ubiquitin mutants that contain only L. Liang al. 2184 haematologica | 2019; 104(11) Figure S7 , USP7 significantly decreased only the K48-linked poly-ubiquitin chain but not any other lysine isopeptide-linked poly-ubiquitin chains (K6, K11, K27, K29, K33 or K63). To further confirm that K48-linked poly-ubiquitin is removed by USP7, we replaced K48 or K63 lysine by arginine (R) and, as shown in Figure 5E , mutation of K48 but not K63 significantly impaired USP7-mediated deubiquitylation. Collectively, these results confirm that USP7 stabilizes GATA1 by removing the K48-linked poly-ubiquitin.
Discussion
Erythropoiesis is a process by which hematopoietic stem cells proliferate and differentiate to eventually produce mature red blood cells. Many cellular and molecular changes occur during this process. Morphological changes include a progressive decrease in cell size, increase in chromatin condensation and enucleation. At the molecular level, high-throughput analyses revealed dramatic changes in both the transcriptome and the proteome. 2, 44 In contrast to extensive studies on transcriptional networks, very little Deubiquitylase USP7 and human erythropoiesis haematologica | 2019; 104(11) 2185 
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is known about the mechanisms by which the proteome is remodeled. Previous studies demonstrated that the balance between ubiquitination and deubiquitination plays important roles in homeostasis of cellular protein pools. 45 In the present study, we documented, for the first time, the role of a deubiquitylase, USP7, in erythroid differentiation. We further documented that the mechanism is stabilization of the erythropoiesis master regulator GATA1. USP7 is a member of a deubiquitinating enzyme family that contains more than 90 genes. 46 USP7 expression is ubiquitous in different cell types: mice with knocked out USP7, which are homozygous for a null allele, show embryonic growth arrest and die between embryonic day 6.5 and 7.5. 47 Furthermore, conditional knockout mice showed that USP7 is required for development of the central nervous system and functional regulatory T cells. 48, 49 We expect that deletion of USP7 in erythroid cells in vivo will led to altered erythropoiesis. We are in the process of generating such conditional knockout mice to define the function of USP7 in vivo. Besides USP7, many other deubiquitinating enzymes are also expressed in erythroid cells, although at lower levels than USP7. It will be interesting in future studies to identify the functional roles of other deubiquitylases during erythroid differentiation. Since each deubiquitinating enzyme has different substrate specificity, 47 it is likely that members of the deubiquitinating enzyme family may regulate different aspects of erythropoiesis via different mechanisms.
As the key transcriptional factor for erythropoiesis, GATA1 protein expression is tightly regulated at several levels. These include translational control by ribosome lev-els, 26, 41 stabilization by HSP70 from caspase 3 cleavage, 27, [38] [39] [40] and degradation by acetylation and phosphorylation-associated ubiquitination. 24 Here we show that knockdown of USP7 by shRNA or inhibition of USP7 activity by USP7specific inhibitors led to dramatic decreases in GATA1 protein levels. Interestingly, USP7 knockdown or inhibition had no effects on the protein levels of RPS19 or HSP70, strongly suggesting that USP7 affects the stability of GATA1 in a direct manner. This notion is supported by our findings that USP7 binds GATA1 directly and stabilizes GATA1 by de-ubiquitination. Specifically, USP7 catalyzes the removal of K48-linked poly-ubiquitin which is a proteasome degradation signal for proteins. Based on our findings and that of others, we propose a schematic model for post-transcriptional regulation of GATA1 ( Figure 6 ). GATA1 functions in the context of multi-protein complexes that include interacting proteins such as FOG1. [50] [51] [52] [53] Although USP7 knockdown or inhibition did not affect the level of FOG1 or NuRD complex (Online Supplementary Figure S8 ), we cannot exclude the possibility that these important GATA1 cofactors or modifications can modulate GATA1-USP7 interactions during erythroid development. Further study is therefore warranted to investigate whether USP7 binds other cofactors such as FOG1 and/or different modifications of GATA1.
Altered expression of GATA1 has been reported in myelodysplastic syndromes 39, 54 and β-thalassemia. 40 However, the mechanisms of the altered GATA1 expression remains to be fully defined. It has been reported that USP7 is associated with several human diseases. [55] [56] [57] Given the close relationship between USP7 and GATA1, demon-strated in our present study, it will be interesting in future studies to examine whether the altered expression of GATA1 may be associated with changes in USP7 expression in certain blood disorders.
In summary, we have uncovered a previously unrecognized role for a deubiquitylase, USP7, in human terminal erythroid differentiation and have identified USP7 as a deubiquitylase of GATA1. Our findings provide new and novel insights into mechanisms of regulating human erythropoiesis.
